将卡里霉素重新用作抗人类冠状病毒的抗病毒药物，包括当前大流行的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）。
Repurposing carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.
作者信息
Yan Haiyan, Sun Jing, Wang Kun, Wang Huiqiang, Wu Shuo, Bao Linlin, He Weiqing, Wang Dong, Zhu Airu, Zhang Tian, Gao Rongmei, Dong Biao, Li Jianrui, Yang Lu, Zhong Ming, Lv Qi, Qin Feifei, Zhuang Zhen, Huang Xiaofang, Yang Xinyi, Li Yuhuan, Che Yongsheng, Jiang Jiandong
机构信息
CAMS Key Laboratory of Antiviral Drug Research, Beijing Key Laboratory of Antimicrobial Agents, NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, China.
出版信息
Acta Pharm Sin B. 2021 Sep;11(9):2850-2858. doi: 10.1016/j.apsb.2021.02.024. Epub 2021 Mar 11.
COVID-19 pandemic caused by SARS-CoV-2 infection severely threatens global health and economic development. No effective antiviral drug is currently available to treat COVID-19 and any other human coronavirus infections. We report herein that a macrolide antibiotic, carrimycin, potently inhibited the cytopathic effects (CPE) and reduced the levels of viral protein and RNA in multiple cell types infected by human coronavirus 229E, OC43, and SARS-CoV-2. Time-of-addition and pseudotype virus infection studies indicated that carrimycin inhibited one or multiple post-entry replication events of human coronavirus infection. In support of this notion, metabolic labelling studies showed that carrimycin significantly inhibited the synthesis of viral RNA. Our studies thus strongly suggest that carrimycin is an antiviral agent against a broad-spectrum of human coronaviruses and its therapeutic efficacy to COVID-19 is currently under clinical investigation.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染引起的2019冠状病毒病（COVID-19）大流行严重威胁全球健康和经济发展。目前尚无有效的抗病毒药物可用于治疗COVID-19及任何其他人类冠状病毒感染。我们在此报告，一种大环内酯类抗生素卡里霉素能有效抑制细胞病变效应（CPE），并降低在被人类冠状病毒229E、OC43和SARS-CoV-2感染的多种细胞类型中病毒蛋白和RNA的水平。加药时间和假型病毒感染研究表明，卡里霉素抑制人类冠状病毒感染的一个或多个进入后复制事件。支持这一观点的是，代谢标记研究表明卡里霉素显著抑制病毒RNA的合成。因此，我们的研究强烈表明，卡里霉素是一种针对广谱人类冠状病毒的抗病毒药物，其对COVID-19的治疗效果目前正在临床研究中。
Zotero 插件